The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: A real-world study from Turkey

Uzunkopru C., Tutuncu M., Gunduz T., GÜMÜŞ H., Sen S., Demir S., ...Daha Fazla

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, cilt.75, sa.7, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 75 Sayı: 7
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1111/ijcp.14158
  • Dergi Adı: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
  • İstanbul Üniversitesi Adresli: Evet

Özet

Background Neuromyelitis optica spectrum disorders (NMOSD) are a group of antibody-mediated chronic inflammatory diseases of the central nervous system. Rituximab is a monoclonal antibody that leads to a reduction in disease activity.